Literature DB >> 22670096

Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancers.

T Di Valentin1, Y Alam, A Ali Alsharm, S Arif, F Aubin, J Biagi, C M Booth, S Bourque, R Burkes, P Champion, B Colwell, C Cripps, M Dallaire, M Dorreen, N Finn, D Frechette, S Gallinger, J Gapski, C Giacomantonio, S Gill, R Goel, R Goodwin, L Grimard, A Grothey, N Hammad, D Hedley, K Jhaveri, D Jonker, Y Ko, M L'espérance, J Maroun, H Ostic, N Perrin, M Rother, E St-Hilaire, M Tehfe, M Thirlwell, S Welch, N Yarom, T Asmis.   

Abstract

The annual Eastern Canadian Colorectal Cancer Consensus Conference was held in Ottawa, Ontario, October 22-23, 2010. Health care professionals involved in the care of patients with colorectal cancer participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of colorectal cancer, such as the use of epidermal growth factor inhibitors in metastatic colon cancer, the benefit of calcium and magnesium with oxaliplatin chemotherapy, the role of microsatellites in treatment decisions for stage II colon cancer, the staging and treatment of rectal cancer, and the management of colorectal and metastatic pancreatic cancers.

Entities:  

Keywords:  Consensus guideline; colorectal cancer; egfri; microsatellites; pancreatic cancer; rectal cancer

Year:  2012        PMID: 22670096      PMCID: PMC3364767          DOI: 10.3747/co.19.931

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  25 in total

1.  New grades for recommendations from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2003-08-05       Impact factor: 8.262

Review 2.  Systematic review of microsatellite instability and colorectal cancer prognosis.

Authors:  S Popat; R Hubner; R S Houlston
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

3.  Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy.

Authors:  Laurence Gamelin; Michèle Boisdron-Celle; Alain Morel; Anne Lise Poirier; Virginie Berger; Erick Gamelin; Christophe Tournigand; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

4.  Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

Authors:  Thierry Conroy; Bernard Paillot; Eric François; Roland Bugat; Jacques-Henri Jacob; Ulrich Stein; Salvador Nasca; Jean-Philippe Metges; Olivier Rixe; Pierre Michel; Emmanuelle Magherini; Aliette Hua; Gael Deplanque
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

5.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

6.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

Authors:  Mario E Lacouture; Edith P Mitchell; Bilal Piperdi; Madhavan V Pillai; Heather Shearer; Nicholas Iannotti; Feng Xu; Mohamed Yassine
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

7.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

Authors:  Philip A Philip; Jacqueline Benedetti; Christopher L Corless; Ralph Wong; Eileen M O'Reilly; Patrick J Flynn; Kendrith M Rowland; James N Atkins; Barry C Mirtsching; Saul E Rivkin; Alok A Khorana; Bryan Goldman; Cecilia M Fenoglio-Preiser; James L Abbruzzese; Charles D Blanke
Journal:  J Clin Oncol       Date:  2010-07-06       Impact factor: 44.544

8.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Authors:  Daniel J Sargent; Silvia Marsoni; Genevieve Monges; Stephen N Thibodeau; Roberto Labianca; Stanley R Hamilton; Amy J French; Brian Kabat; Nathan R Foster; Valter Torri; Christine Ribic; Axel Grothey; Malcolm Moore; Alberto Zaniboni; Jean-Francois Seitz; Frank Sinicrope; Steven Gallinger
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

Review 9.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

Authors:  Gaëtan Des Guetz; Olivier Schischmanoff; Patrick Nicolas; Gérard-Yves Perret; Jean-François Morere; Bernard Uzzan
Journal:  Eur J Cancer       Date:  2009-05-06       Impact factor: 9.162

10.  Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway.

Authors:  Laurence Gamelin; Olivier Capitain; Alain Morel; Agnes Dumont; Sory Traore; Le Bouil Anne; Simard Gilles; Michele Boisdron-Celle; Erick Gamelin
Journal:  Clin Cancer Res       Date:  2007-11-01       Impact factor: 12.531

View more
  1 in total

1.  Rectal cancer : when is the local recurrence risk low enough to refrain from the aim to prevent it?

Authors:  M L Sautter-Bihl; W Hohenberger; R Fietkau; C Rödel; H Schmidberger; R Sauer
Journal:  Strahlenther Onkol       Date:  2013-02       Impact factor: 3.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.